Quantifying the role of natalizumab in health and economic outcomes in multiple sclerosis.

The American journal of managed care

Volumn 16, Issue 6 Suppl, 2010, Pages

  Brandes, David W ^a   Shaya, Fadia T ^b   Pill, Michael W ^b  

^a Hope Neurology   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTEGRIN; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; NATALIZUMAB;

AGE; COST; DISEASE COURSE; DRUG ANTAGONISM; ECONOMICS; HEALTH SERVICE; HOSPITALIZATION; HUMAN; MULTIPLE SCLEROSIS; QUALITY OF LIFE; REVIEW; SEX DIFFERENCE; UTILIZATION REVIEW;

AGE FACTORS; ANTIBODIES, MONOCLONAL; COSTS AND COST ANALYSIS; DISEASE PROGRESSION; HEALTH SERVICES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTEGRIN ALPHA CHAINS; MULTIPLE SCLEROSIS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; SEX FACTORS;

EID: 77958119504     PISSN: None     EISSN: 19362692     Source Type: Journal    
DOI: None     Document Type: Review

References (0)